Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/STOML2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/STOML2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/STOML2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/STOML2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STOML2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STOML2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STOML2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STOML2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STOML2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STOML2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725229 | Prostate | BPH | purine-containing compound biosynthetic process | 55/3107 | 200/18723 | 6.64e-05 | 6.59e-04 | 55 |
GO:00061649 | Prostate | BPH | purine nucleotide biosynthetic process | 52/3107 | 191/18723 | 1.37e-04 | 1.22e-03 | 52 |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:00018199 | Prostate | BPH | positive regulation of cytokine production | 105/3107 | 467/18723 | 5.18e-04 | 3.66e-03 | 105 |
GO:00518818 | Prostate | BPH | regulation of mitochondrial membrane potential | 24/3107 | 74/18723 | 6.06e-04 | 4.16e-03 | 24 |
GO:00508526 | Prostate | BPH | T cell receptor signaling pathway | 35/3107 | 123/18723 | 6.68e-04 | 4.48e-03 | 35 |
GO:00091657 | Prostate | BPH | nucleotide biosynthetic process | 60/3107 | 254/18723 | 2.34e-03 | 1.28e-02 | 60 |
GO:00466313 | Prostate | BPH | alpha-beta T cell activation | 40/3107 | 156/18723 | 2.58e-03 | 1.38e-02 | 40 |
GO:19012937 | Prostate | BPH | nucleoside phosphate biosynthetic process | 60/3107 | 256/18723 | 2.83e-03 | 1.49e-02 | 60 |
GO:00326232 | Prostate | BPH | interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:00326632 | Prostate | BPH | regulation of interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:004603419 | Prostate | Tumor | ATP metabolic process | 122/3246 | 277/18723 | 1.71e-25 | 5.33e-22 | 122 |
GO:000611918 | Prostate | Tumor | oxidative phosphorylation | 77/3246 | 141/18723 | 9.55e-24 | 1.98e-20 | 77 |
GO:000906017 | Prostate | Tumor | aerobic respiration | 87/3246 | 189/18723 | 4.34e-20 | 3.37e-17 | 87 |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:004533317 | Prostate | Tumor | cellular respiration | 93/3246 | 230/18723 | 8.89e-17 | 2.22e-14 | 93 |
GO:001598017 | Prostate | Tumor | energy derivation by oxidation of organic compounds | 116/3246 | 318/18723 | 1.54e-16 | 3.54e-14 | 116 |
GO:000683917 | Prostate | Tumor | mitochondrial transport | 84/3246 | 254/18723 | 7.17e-10 | 3.57e-08 | 84 |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000914418 | Prostate | Tumor | purine nucleoside triphosphate metabolic process | 38/3246 | 88/18723 | 1.28e-08 | 4.66e-07 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STOML2 | insertion | In_Frame_Ins | novel | c.869_870insTGGGGA | p.Ala290_Lys291insGlyAsp | p.A290_K291insGD | Q9UJZ1 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
STOML2 | insertion | In_Frame_Ins | novel | c.868_869insAGCTGGGCTTGGCCAGGGAGT | p.Ala290delinsGluLeuGlyLeuAlaArgGluSer | p.A290delinsELGLARES | Q9UJZ1 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
STOML2 | SNV | Missense_Mutation | rs763483882 | c.215G>A | p.Arg72Gln | p.R72Q | Q9UJZ1 | protein_coding | tolerated(0.09) | benign(0.094) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STOML2 | SNV | Missense_Mutation | rs753222022 | c.511N>T | p.Arg171Cys | p.R171C | Q9UJZ1 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STOML2 | SNV | Missense_Mutation | rs201944176 | c.776G>A | p.Arg259Gln | p.R259Q | Q9UJZ1 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
STOML2 | SNV | Missense_Mutation | | c.1062G>T | p.Lys354Asn | p.K354N | Q9UJZ1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.003) | TCGA-G4-6303-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
STOML2 | SNV | Missense_Mutation | | c.445N>A | p.Glu149Lys | p.E149K | Q9UJZ1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
STOML2 | SNV | Missense_Mutation | novel | c.628N>T | p.Thr210Ser | p.T210S | Q9UJZ1 | protein_coding | tolerated(0.36) | benign(0.098) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STOML2 | SNV | Missense_Mutation | rs781632715 | c.512N>A | p.Arg171His | p.R171H | Q9UJZ1 | protein_coding | tolerated(0.1) | possibly_damaging(0.806) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
STOML2 | SNV | Missense_Mutation | rs201944176 | c.776N>A | p.Arg259Gln | p.R259Q | Q9UJZ1 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |